$6.69 +0.32 (4.99%)
Dogwood Therapeutics, Inc. Common Stock (DWTX)
Dogwood Therapeutics, Inc. (DWTX) is a biotechnology company focused on developing innovative therapies targeting the central nervous system and ophthalmic conditions. The company leverages its expertise in drug discovery and development to create novel treatments for neurological disorders, with an emphasis on improving patient outcomes through precision medicine approaches.
Company News
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
Dogwood Therapeutics reported ongoing Phase 2b trial for Halneuron®, a potential treatment for chemotherapy-induced neuropathic pain, with 52 patients enrolled and interim data expected in Q4 2025. The company experienced increased research and development expenses and reported a net loss of $3.8 million for Q2 2025.